收起

掌上阜外
官方微信
官方微博
我要挂号
意见信箱
我要求职
我要进修
志愿服务
返回顶部
  • 人才队伍
  • 国家高层次人才

荆志成

发布时间:2015-11-26 14:38:31

协和学者

教育部新世纪优秀人才

"国家杰出青年科学基金“获得者

科技北京百名领军人才

上海市领军人才

上海市浦江人才

上海市曙光学者

办公电话:010-88396108

课题组研究方向:肺动脉高压及血栓性疾病的分子机制及临床转化研究  

研究方向介绍:
 
   荆志成教授课题组专注于肺动脉高压及血栓性疾病的分子机制和临床转化研究。我们将基础研究与临床实践相结合,联合运用遗传学、表观遗传学、蛋白组学、转录组学等多种手段寻找致病基因、易感基因与修饰基因,探讨遗传与环境、遗传与表观遗传、遗传与雌激素在肺动脉高压及血栓性疾病发生发展中的作用,利用动物模型和细胞模型研究疾病基因在血管重构、右心重塑、血栓与止血、血小板与内皮损伤等病理生理过程中的功能,阐明关键环节和信号通路,发现靶点。对于重要靶点,寻找和开发小分子化合物,阐明药理机制,探讨治疗有效性、安全性,加速转化。
 Our group focuses on translational research of pulmonary hypertension and thrombotic diseases.We explore the novel disease-causing genes or modifier genes which are involved in the initiation and development of pulmonary hypertension and thrombotic diseases using high-throughput tools, such as functional genomics, molecular genetics, epigenetics and proteomics. With animal models and cell models, we then study the function of novel disease-related genes in the pathophysiology of vascular remodeling, right heart remodeling, thrombosis and hemostasis, platelets and endothelial cells injury. After clarifying the molecular mechanism and signaling pathways, we try to develop small molecule compounds for important targets and explore treatment efficacy and safety.
 
 
代表性的SCI论文(5篇): 荆志成教授为第一和/或通讯作者
 1. Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, Li J, Gao L, Qu JM, Kawut SM, Jing ZC*. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013; 187(3): 303-310. (
影响因子: 11.041)
 2. Jing ZC*, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127(5): 624-633. (
全球Leading PI,影响因子: 15.202)
 3. Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY, Zhang ZL, Jing ZC*. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways. Eur Respir J. 2013; 41(5)
1116-1125.(影响因子: 6.355
 4. Liu D, Wu WH, Mao YM, Yuan P, Zhang R, Ju FL, Jing ZC*. BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012; 5(5): 511-518. (
影响因子: 6.728)
 5. Fan YF, Zhang R, Jiang X, Wen L, Wu DC, Liu D, Yuan P, Wang YL, Jing ZC*. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovascular Research. 2013 Aug 1;99(3):395-403. (
影响因子:5.940)

研究团队的合影:
 
 

上一篇: 唐熠达

下一篇: 没有了!